

Srf1 Is a Novel Regulator of Phospholipase D Activity and Is Essential to Buffer the Toxic Effects of C16:0 Platelet Activating Factor

Michael A. Kennedy¹, Nazir Kabbani¹, Jean-Philippe Lambert¹, Leigh Anne Swayne¹, Fida Ahmed¹, Daniel Figeys¹, Steffany A. L. Bennett¹, Jennnifer Bryan², Kristin Baetz^{1*}

1 Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Canada, **2** Michael Smith Laboratories and Department of Statistics, University of British Columbia, Vancouver, Canada

Abstract

During Alzheimer's Disease, sustained exposure to amyloid- β_{42} oligomers perturbs metabolism of ether-linked glycerophospholipids defined by a saturated 16 carbon chain at the *sn*-1 position. The intraneuronal accumulation of 1-*O*-hexadecyl-2-acetyl-*sn*-glycerophosphocholine (C16:0 PAF), but not its immediate precursor 1-*O*-hexadecyl-*sn*-glycerophosphocholine (C16:0 *lyso*-PAF), participates in signaling tau hyperphosphorylation and compromises neuronal viability. As C16:0 PAF is a naturally occurring lipid involved in cellular signaling, it is likely that mechanisms exist to protect cells against its toxic effects. Here, we utilized a chemical genomic approach to identify key processes specific for regulating the sensitivity of *Saccharomyces cerevisiae* to alkyacylglycerophosphocholines elevated in Alzheimer's Disease. We identified ten deletion mutants that were hypersensitive to C16:0 PAF and five deletion mutants that were hypersensitive to C16:0 *lyso*-PAF. Deletion of *YDL133w*, a previously uncharacterized gene which we have renamed *SRF1* (Spo14 Regulatory Factor 1), resulted in the greatest differential sensitivity to C16:0 PAF over C16:0 *lyso*-PAF. We demonstrate that Srf1 physically interacts with Spo14, yeast phospholipase D (PLD), and is essential for PLD catalytic activity in mitotic cells. Though C16:0 PAF treatment does not impact hydrolysis of phosphatidylcholine in yeast, C16:0 PAF does promote delocalization of GFP-Spo14 and phosphatidic acid from the cell periphery. Furthermore, we demonstrate that, similar to yeast cells, PLD activity is required to protect mammalian neural cells from C16:0 PAF. Together, these findings implicate PLD as a potential neuroprotective target capable of ameliorating disruptions in lipid metabolism in response to accumulating oligomeric amyloid- β_{42} .

Citation: Kennedy MA, Kabbani N, Lambert J-P, Swayne LA, Ahmed F, et al. (2011) Srf1 Is a Novel Regulator of Phospholipase D Activity and Is Essential to Buffer the Toxic Effects of C16:0 Platelet Activating Factor. *PLoS Genet* 7(2): e1001299. doi:10.1371/journal.pgen.1001299

Editor: Hiten D. Madhani, University of California San Francisco, United States of America

Received: July 13, 2010; **Accepted:** January 7, 2011; **Published:** February 10, 2011

Copyright: © 2011 Kennedy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by an Early Researcher Award from the Ontario Government to KB; operating support from the Canadian Institute of Health Research (CIHR, MOP 89999) to SALB, DF, and KB; a Strategic Training Initiative in Health Research (STIHR)/CIHR Training Grant in Neurodegenerative Lipidomics to SALB, DF, and KB; and operating support from the Natural Sciences and Engineering Research Council (NSERC) to JB. KB is a Canada Research Chair (CRC) in Chemical and Functional Genomics. DF is a CRC in Proteomics and Systems Biology. MAK and LAS were supported by an Institute of Aging and STIHR/CIHR Training Grant in Neurodegenerative Lipidomics post-doctoral fellowship. LAS was also supported by the Heart and Stroke Foundation Centre for Stroke Recovery and a Vision 2010 (Ministry of Research and Innovation, Ontario, University of Ottawa, Parkinson's Research Network) postdoctoral fellowship. FA was supported by a NSERC Canadian Graduate Vanier Scholarship. J-PL was supported by an Ontario Graduate Scholarship. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: kbaetz@uottawa.ca

Introduction

Perturbations in glycerophosphocholine (GPC) metabolism are linked to the pathogenesis of Alzheimer's Disease (AD) with the accumulation of choline-containing lipids in AD patients associated with accelerated cognitive decline [1–4]. Soluble amyloid- β_{42} ($A\beta_{42}$) oligomers can increase hydrolysis of structural membrane lipids by activating cytosolic phospholipase A_2 (cPLA₂), a Group IVa PLA₂ that preferentially hydrolyzes arachidonic acid from the *sn*-2 position of 1-*O*-alkyl-2-arachidonoyl- and 1-*O*-acyl-2-arachidonoyl- glycerophospholipids [2,5,6]. Sustained activation results in arachidonic acid signaling cascades, as well as the intraneuronal accumulation of choline-containing second messengers [1,2,5].

The fate and functions of these GPC second messengers are of particular interest. Recent evidence points to the accumulation of specific choline-containing metabolites [1,2,5]. Underlying mech-

anisms have yet to be fully elucidated. PC(*O*-16:0/2:0) platelet activating factor (PAF) species are elevated in AD brain and human neurons exposed to $A\beta_{42}$ [1]. Of these elevated species, 1-*O*-hexadecyl-2-acetyl-*sn*-glycerophosphocholine (C16:0 PAF), but not its immediate precursor 1-*O*-hexadecyl-*sn*-glycerophosphocholine (C16:0 *lyso*-PAF), is implicated in $A\beta_{42}$ toxicity [1]. Rising intraneuronal concentrations of C16:0 PAF activate an endoplasmic reticulum (ER)-stress signaling cascade leading to the hyperphosphorylation of tau that ultimately compromises neuronal viability [1]. Molecular and pharmacological approaches designed to promote the hydrolysis of C16:0 PAF to C16:0 *lyso*-PAF and/or block downstream signaling are sufficient to inhibit $A\beta$ -mediated neurotoxicity [7–10]. These findings underscore the importance of this lipid species in Alzheimer's disease and emphasize the rationale for identifying key targets involved in shielding its toxic effects and/or promoting its hydrolysis and inactivation.

Author Summary

Accelerated cognitive decline in Alzheimer's patients is associated with accumulation of choline-containing lipids. One of these lipids, C16:0 platelet activating factor (PAF), is specifically elevated in brains of Alzheimer's patients. As elevated exposure to C16:0 PAF ultimately leads to neuronal death, it is crucial to identify underlying mechanisms that mitigate the toxic effects of this lipid. In this study we exploit the conserved biology between humans and baker's yeast to identify key genes that are essential to buffer the toxic effects of C16:0 PAF. We found that Srf1, or Spo14 Regulatory Factor 1, the previously uncharacterized protein Ydl133w, is essential for mitigating the toxic effects of C16:0 PAF in yeast. We determine that Srf1 interacts with yeast phospholipase D (PLD) Spo14 and is required for PLD activity in mitotic cells. Hence we discovered a novel regulator of PLD in yeast. Further, we extend our studies to higher eukaryotes demonstrating that PLD is required to buffer the neurotoxic effect of C16:0 PAF. Our study suggests that therapeutic strategies modulating PLD activity may be effective in ameliorating Alzheimer's Disease pathology associated with disruptions in lipid metabolism.

Unbiased approaches exploiting the cross-species conservation of biochemical pathways between man and the budding yeast *Saccharomyces cerevisiae* have proven to be successful in elucidating the mode-of-action of various compounds [11]. Further, *S. cerevisiae* has also been used as a model organism to delineate key aspects of eukaryotic lipid metabolism and to investigate various neurodegenerative diseases [12,13]. Despite conservation of the PAF metabolic pathway genes and detection of PAF species in yeast [14], the function of the different species in yeast is currently unclear, although PAF species are suggested to play a role in cell cycle progression [15,16]. Similar to the effects of PAF on mammalian cells, yeast cells treated with PAFs and structurally related alkylacylglycerophosphocholine analogs induce disruptions in lipid metabolism and reduce viability [17,18]. Interestingly, *S. cerevisiae* strains harboring deletions for enzymes involved in phosphatidic acid (PA) metabolism, including phospholipase D (*SPO14*) and glycerol 3-phosphate acyltransferase (*SCT1*), exhibit increased susceptibility to PAF species and other choline-containing lipids suggesting an essential role for PA in mediating

the toxic effects of PAFs [17]. Whether the toxic effects of alkylacylglycerolipids are solely dependent upon *SPO14* and similar pathways impinging upon PA metabolism or whether other aspects of cellular metabolism are involved has not been systematically assessed at a genome-wide level. Moreover, it remains unclear why PAF second messengers accumulate in AD tissue without compensatory metabolism.

To identify additional requisite proteins and/or pathways which serve to regulate the cytotoxic affects of C16:0 PAF, we performed genome-wide yeast chemical genomic screens with both C16:0 PAF (pathogenic in AD) and C16:0 *lyso*-PAF (non-pathogenic in AD). We found that the two PAF species identify largely distinct chemical genetic interactions and that the deletion mutant that exhibited the greatest differential sensitivity to the pathogenic C16:0 PAF species was *YDL133w*, a previously uncharacterized ORF encoding a putative transmembrane protein with unknown function. Upon subsequent investigation we determined that Ydl133w physically interacts with Spo14 and is required for PLD catalytic activity in *S. cerevisiae*. Importantly, Ydl133w, here in referred to as Srf1 (Spo14 Regulatory Factor 1), represents the only reported regulator of Spo14 required for PLD catalytic activity in mitotic cells. We report that though C16:0 PAF does not impact global PLD activity, it does cause the delocalization of Spo14 and PA from the periphery. Importantly our observations can be extended from the yeast model system as PLD activity in mammalian cells was found to confer protection against the toxic effects of C16:0 PAF.

Results

Sensitivity of yeast to C16:0 PAF and C16:0 *lyso*-PAF

Previous studies have determined that, similar to neuronal cells [1], *S. cerevisiae* are sensitive to C16:0 PAF [17]. To determine whether C16:0 PAF and C16:0 *lyso*-PAF differentially impact the growth of *S. cerevisiae* and to identify an appropriate working concentration range for these lipids in subsequent studies we performed liquid growth curve analysis using wild type haploid yeast cultured with increasing concentrations of C16:0 PAF, C16:0 *lyso*-PAF or ethanol (carrier control). As expected, C16:0 PAF inhibited wild type haploid yeast growth in liquid culture in a concentration-dependent manner whereas C16:0 *lyso*-PAF was found to be comparatively less toxic at similar concentrations (Figure 1). Although both lipids impact viability at higher concentrations, the distinct effects of these two lipids at lower




Figure 1. The differential sensitivity of yeast to C16:0 PAF and C16:0 *lyso*-PAF. Growth of wild type (YPH499) strain (OD_{600}) as a function of time in hours. Wild type yeast cells were grown in YPD liquid culture with or without C16:0 PAF or C16:0 *lyso*-PAF as indicated. Growth curves were performed in triplicate and the error bars represent 1 standard deviation. doi:10.1371/journal.pgen.1001299.g001

concentrations have not previously been appreciated and parallels their toxicity to neuronal cells [1,19].

C16:0 PAF and C16:0 *lyso*-PAF chemigenomic screen

To identify critical proteins and/or pathways which are involved in regulating the cytotoxic effects of C16:0 PAF, the yeast haploid deletion mutant array (DMA) was robotically pinned onto agar plates containing either ethanol or a sublethal concentration of C16:0 PAF (120 μ M). To facilitate the identification of potentially AD-relevant pathways we also screened with equimolar concentrations of C16:0 *lyso*-PAF (120 μ M) to distinguish between pathways that regulate AD-associated (C16:0 PAF) and non-associated (C16:0 *lyso*-PAF) phenotypes. The screen was performed in triplicate and 90 strains displaying putative increased sensitivity to C16:0 PAF or C16:0 *lyso*-PAF were further subjected to quantitative liquid growth curve measurements in the presence of C16:0 PAF, *lyso*-PAF, or ethanol (Table S1). A reduced concentration of 40 μ M was employed in liquid cultures as this was found to cause moderate growth inhibition in wild type cells, thereby permitting quantitative analysis of the sensitivity of the individual strains to C16:0 PAF and C16:0 *lyso*-PAF relative to ethanol treatment using logistic growth curve analysis (LGCA, see

Material and Methods and Text S1 for details). This rigorous methodology accounts for the repeated measurements of individual liquid cultures and also exploits full, sigmoidal growth curves, since it does not assume exponential growth. Furthermore, we also normalize for plate and plate-treatment effects. LGCA revealed 13 deletion mutants that were hypersensitive to at least one PAF species, compared to the wild type response: ten strains were hypersensitive to C16:0 PAF, five strains were hypersensitive to C16:0 *lyso*-PAF, and two overlapping strains were hypersensitive to both (Bonferroni corrected p-value <0.04; Figure 2A, Table S1). As expected, the *spo14* mutant was hypersensitive to C16:0 PAF as has previously been described [17]. *set1* mutants have also been reported to be hypersensitive to C16:0 PAF [17], and though it did not make our stringent cut-off, the *set1* mutant was ranked 13th in sensitivity to C16:0 PAF (Table S1).

Using LGCA we also assessed the differential sensitivity of each deletion mutant to C16:0 PAF versus C16:0 *lyso*-PAF. At the 40 μ M treatment level, wild type cells exhibited approximately the same growth inhibition when exposed to either PAF species and we defined differential sensitivity as a departure from the status quo. Eleven deletion mutants exhibited differential sensitivity to one of the PAF species (Bonferroni-corrected p-value <0.04,




Figure 2. C16:0 PAF and C16:0 *lyso*-PAF chemical genetic screen. (A) Chemical genetic interaction network for C16:0 PAF and C16:0 *lyso*-PAF. Deletion mutants that displayed a hypersensitivity to either 40 μ M C16:0 PAF and/or C16:0 *lyso*-PAF (Bonferroni corrected p-value <0.04) are represented by nodes that are color coded according to their SGD cellular roles and/or through review of literature. Interactions are represented by edges. (B) Plot of the differential sensitivity (in mins) = $\alpha_{g-PAF} - \alpha_{g-L-PAF}$ for wild type (wt) along with the 11 strains identified that had differential sensitivity to one of the PAF species (Bonferroni corrected p-value <0.04). Strains that are hypersensitive to C16:0 PAF have positive differential sensitivity, while strains that are hypersensitive to C16:0 *lyso*-PAF have negative differential sensitivity. doi:10.1371/journal.pgen.1001299.g002

Figure 2B and Table S1). Of the two mutants that were identified in both screens, *agp2Δ* cells were equally sensitive to both lipids whereas *taf14Δ* displayed greater sensitivity to C16:0 PAF. Though LGCA identified *ccs1Δ* as being sensitive to C16:0 PAF its differential sensitivity was not significant. The differential sensitivity of four strains was striking. Namely, *nup84Δ* cells displayed the greatest differential sensitivity to C16:0 *lyso*-PAF, whereas *sf1Δ*, *snf6Δ* and *spo14Δ* were significantly more sensitive to C16:0 PAF than C16:0 *lyso*-PAF. The largely distinct chemical genetic profiles for C16:0 PAF and C16:0 *lyso*-PAF indicates that these related alkylacylglycerophospholipids impact upon distinct cellular pathways in yeast.

Srf1 interacts with Spo14

Our results indicate that at the 40 μM treatment level, Srf1 is pivotal for buffering the effects of C16:0 PAF. The biological function(s) of Srf1 is unknown but it is predicted to be a transmembrane protein. Therefore we sought to decipher its cellular function by identifying proteins that interact with Srf1. As traditional tandem affinity purification (TAP) protocols were not successful in purifying Srf1-TAP [data not shown and ref. 20,21], we utilized a less stringent single step affinity purification approach based on the modified chromatin immunopurification (mChIP) technique [22]. Though this technique was developed for improving the purification of insoluble chromatin associated proteins, it is also applicable to other subclasses, including membrane associated proteins [23]. Using mChIP we successfully purified Srf1-TAP and identified five co-purifying proteins by mass spectrometry, of which the largest number of peptides correspond to Spo14 (Figure 3). The physical interaction between Srf1 and Spo14, combined with the sensitivity of the corresponding deletion mutants to C16:0 PAF [Figures 2, 4 and ref. 17] suggest Srf1 may work in a complex with Spo14 to regulate PA metabolism.

Srf1 and Spo14 buffer the toxic effects of C16:0 PAF

To determine if Srf1 and Spo14 function together or work in parallel pathways, we compared the sensitivity of the *sf1Δspo14Δ* double mutant to C16:0 PAF with that of the single mutants (Figure 4A). In agreement with our chemical genomic screen, *sf1Δ* cells display greater sensitivity to C16:0 PAF than *spo14Δ* cells. Interestingly, deletion of both *SRF1* and *SPO14* did not result in an additive increase in C16:0 PAF sensitivity but rather, the double

mutant and *spo14Δ* exhibited similar sensitivity to C16:0 PAF. This indicates that *spo14Δ* is epistatic to *sf1Δ* and is in agreement with the hypothesis that Spo14 and Srf1 are in a complex and not in parallel pathways. In light of the physical interaction between Srf1 and Spo14, one interpretation of this result is that Spo14 activity is misregulated in the absence of Srf1. To further examine this possibility, we overexpressed *SPO14* in wild type, *sf1Δ* and *spo14Δ* strains (Figure 4B). Overexpression of catalytically active (*SPO14* and *GFP-SPO14*) [24], but not catalytically inactive (*GFP-SPO14^{K6-H}*) [24], *SPO14* was sufficient to rescue the *spo14Δ* strain from C16:0 PAF-mediated toxicity, whereas overexpression of *SPO14* was not found to have any effect in *sf1Δ* cells. Our findings suggest that Srf1 functions either downstream of Spo14 in mediating an aspect of PA-dependent signaling or directly upon the regulation of Spo14 function. In consideration of the physical interaction between Spo14 and Srf1 (Figure 3), it is more likely that Spo14 and Srf1 act in concert to mediate choline hydrolysis and PA production.

Srf1 is not essential for sporulation

Although dispensable in mitotic cells, Spo14 is strictly required for the progression of *S. cerevisiae* through meiosis [25]. This observation provides a simple approach to measure the effects of potential Spo14 interacting partners upon its catalytic activity during meiosis. Indeed, *GCSI*, which encodes an indirect regulator of Spo14 catalytic activity is essential for sporulation [26]. Therefore, we assessed whether deletion of *SRF1* would result in impaired spore formation. In contrast to *spo14Δ* diploids that failed to sporulate, *sf1Δ* diploids displayed only minor impairments in sporulation which were associated with an increased frequency of dyads (Table 1). The modest effect of *SRF1* on sporulation is in agreement with previous reported genome-wide studies [27], and suggests that Srf1 may have only a minor or no impact on Spo14 activity during meiosis or that Srf1 may function via PLD-independent mechanism during sporulation.

Srf1 regulates Spo14 catalytic activity in mitotic cells

Despite the limited impact on sporulation, there is a possibility that Srf1 may regulate PLD activity in mitotic cells. Therefore, we sought to examine whether Srf1 could modify Spo14 catalytic activity or localization in mitotic cells. The former possibility was directly assessed by measuring PLD activity in particulate fractions




Figure 3. mChIP of Srf1-TAP co-purifies Spo14. (A) Silver-stained 4-12% NuPAGE gels of the protein network associated with Srf1-TAP (YKB2270). The arrow indicates the position of Srf1-TAP, the * indicates the position of Spo14 and IgG indicates the position of the immunoglobulin. (B) An aliquot of the purification was used for Western blot analysis using anti-TAP-tagged antibodies (α -TAP). (C) Summary of mass spectrometry analysis of the proteins identified in the Srf1-TAP mChIP with high confidence. Spo14 and Srf1-TAP were the two most abundant proteins identified in the Srf1-TAP purification.

doi:10.1371/journal.pgen.1001299.g003




Figure 4. Characterization of a genetic interaction between *SPO14* and *SRF1* revealed by C16:0 PAF. (A) Sensitivity of *srf1Δ* to C16:0 PAF is suppressed by *spo14Δ*. Wild type (YPH500), *spo14Δ* (YKB2076), *srf1Δ* (YKB1164) and *srf1Δspo14Δ* (YKB2080) cells were plated in five-fold serial dilution onto YPD or YPD supplemented with C16:0 PAF as indicated. The plates were incubated for 3 days at 30°C. (B) Overexpression of *SPO14* does not alleviate the sensitivity of *srf1Δ* cells to C16:0 PAF. Wild type (YPH500), *srf1Δ* (YKB1164), and *spo14Δ* (YKB2076) cells transformed with pRS415 (vector), pME962 (*SPO14*), pME1096 (*GFP-SPO14*) or pME1130 (*GFP-SPO14*^{K-H}) [24] were plated in five-fold serial dilution onto SD-Leu or SD-Leu supplemented with C16:0 PAF as indicated. The plates were incubated for 2 days at 30°C. The growth of all strains tested was moderately improved on minimal media compared with YPD at equivalent concentrations of C16:0 PAF. This is reflected by the observed differences in growth for both the wild type and *srf1Δ* strain when comparing panels (A) and (B). doi:10.1371/journal.pgen.1001299.g004

prepared from wild type and mutant strains using a previously described methodology employing a fluorescently labeled phosphatidylcholine derivative as a PLD substrate [28,29]. Production of PA and phosphatidyl butanol (Pbt), a product of transphosphatidylolation, was evident in wild type particulate preparations but was completely absent in *srf1Δ*, *spo14Δ* and *srf1Δspo14Δ* mutant strains (Figure 5A). This result indicates that Srf1 may contribute to particulate-associated PLD catalytic activity in mitotic cells. As we have demonstrated that Spo14 physically interacts with Srf1, a predicted transmembrane protein, we sought to determine whether the deletion of *SRF1* promotes the loss of Spo14 from the particulate fraction. To test this, particulate and cytosolic fractions were prepared from strains transformed with either an empty vector control or a plasmid

expressing HA-tagged *SPO14* [24]. The absence of PLD activity in *srf1Δ* strains is not a consequence of altered partitioning of Spo14 catalytic activity between particulate and cytosolic fractions in these cells as catalytic activity was absent from both fractions (Figure 5B). Furthermore, western blot analysis demonstrates that HA-Spo14 remains associated with the particulate fraction independent of Srf1 (Figure 5C). Interestingly, HA-Spo14 protein levels are consistently reduced in *srf1Δ* mutants (~30% less HA-Spo14 as determined by densitometry). However, the absence of detectable PLD activity cannot be fully explained by the exclusion of Spo14 from the particulate fraction or a reduction in Spo14 protein levels (Figure 5C) thereby further implicating a biological role for Srf1 in regulating Spo14 catalytic activity during mitosis.

Table 1. Sporulation efficiency of *srf1Δ* cells.

Strain	Genotype	% Sporulation ^a	% Dyads ^a
YKB2239	Wild type	28 (5.4)	4 (2.4)
YKB2079	<i>spo14Δ</i>	0 (0)	NA
YKB2078	<i>srf1Δ</i>	24 (8.1)	22 (4.8)
YKB2240	<i>spo14Δsrf1Δ</i>	0 (0)	NA

^a Percentage sporulation and dyads were determined by brightfield microscopy following incubation for 3 days at 25°C in liquid YP-acetate sporulation media. The number of spores in a minimum of 300 total cells from 3 independent experiments was calculated and reported with SEM indicated in parentheses. NA, not applicable.

doi:10.1371/journal.pgen.1001299.t001

PLD-dependent inhibition of C16:0 PAF-mediated signaling and toxicity

Our findings implicating Srf1 in both buffering against the toxic effects of C16:0 PAF and in regulating mitotic PLD activity, underscores the importance of the PLD pathway in protecting yeast cells from C16:0 PAF. Therefore, we next sought to address the effects of C16:0 PAF on the subcellular localization and activity of Spo14. As had been previously shown [24,30], in untreated or vehicle treated wild type (WT) cells, GFP-Spo14 displays modest peripheral and diffuse cytosolic localization (Figures 6A and S1). Deletion of *SRF1* was not observed to grossly affect the subcellular localization of GFP-Spo14 in untreated or vehicle treated cells. However, addition of C16:0 PAF resulted in the rapid loss of GFP-Spo14 at the cell periphery with a concomitant accumulation of GFP-Spo14 at discrete foci or intracellular aggregates in $61 \pm 7\%$ of wild type cells (Figures 6A, 6B and Figure S1). However, treatment with C16:0 PAF resulted in significantly fewer foci in the *srf1Δ* background ($9 \pm 2\%$) suggesting Srf1 plays a role in the intracellular trafficking of Spo14 under C16:0 PAF treatment (Figures 6A, B S1). As a secondary method to explore the impact of C16:0 PAF on PLD localization we looked at the impact of C16:0 PAF on wild type cells expressing GFP-Q2; GFP tagged to the PA-binding domain of the transcription factor Opi1 [31]. GFP-Q2 localizes to both the periphery and nucleus in wild type cells, however in *spo14Δ* cells the peripheral signal is lost indicating PA and hence PLD activity is no longer concentrated at the periphery [31]. Treatment of wild type cells expressing GFP-Q2 with C16:0 PAF resulted in the loss of GFP-Q2 from the periphery (Figure 6C), mirroring the effect of C16:0 PAF upon GFP-Spo14 (Figure 6C). Together our studies support C16:0 PAF-mediated changes in the subcellular localization of GFP-Spo14 which are at least in part dependent upon Srf1 expression. Interestingly although C16:0 PAF treatment consistently resulted in the formation GFP-Spo14 aggregate structures; we never detected localization of GFP-Q2 in a similar structure. This suggests that, potentially, GFP-Spo14 aggregates that form upon PAF treatment are no longer catalytically active or alternatively that the PA produced is not accessible to GFP-Q2. Therefore we also assessed whether the C16:0 PAF-dependent changes in the subcellular localization of GFP-Spo14 and PA were the result of changes in Spo14 catalytic activity, partitioning within subcellular compartments or expression levels. Addition of C16:0 PAF was not observed to impact the catalytic activity of PLD localized to particulate fractions (Figure 6D) which is in agreement with previous *in vitro* findings [28]. Furthermore, C16:0 PAF treatment did not dissociate PLD activity (Figure 6D) or GFP-Spo14 (Figure 6E) from the particulate fraction, which suggests the C16:0 PAF-dependent GFP-Spo14 aggregate structures are likely still associated with a membranous compartment. Though the production of PA has




Figure 5. Srf1 regulates phospholipase D catalytic activity in mitotic cells. (A) Extracts of the particulate fraction were prepared from wild type (YPH500), *spo14Δ* (YKB2076), *srf1Δ* (YKB1164) and *srf1Δspo14Δ* (YKB2080) cells and incubated with BODIPY labeled glycerophosphocholine (BPC) as described in Materials and Methods. Purified *Streptomyces chromofuscus* (*S. chromofuscus*) PLD was included as a positive control for the production of phosphatidic acid (PA). In addition, since Spo14, but not *S. chromofuscus* PLD, can convert *n*-butanol to phosphatidylbutanol (PBt), PLD activity was also assessed by including *n*-butanol (1% v/v) in the reaction mixture. Reactions were allowed to proceed for 40 min at 30°C before separating reaction products by TLC. The absence of Srf1 resulted in a complete loss of detectable PLD activity similar to that observed in *spo14Δ* mutant strains. (B) Strains listed above were transformed with either pRS415, an empty vector (vector), or pME940, a *CEN* vector expressing HA-SPO14 (*SPO14*) [24]. Particulate (P) and cytosolic (C) fractions were assessed for PLD as described above. Deletion of *SRF1* does not result in altered partitioning of PLD activity into the cytosolic fraction and expression of HA-Spo14 does not rescue PLD activity in *srf1Δ* strains. (C) Particulate and cytosolic fractions prepared as in (B) were separated by SDS-PAGE and analyzed by immunoblotting using anti-HA antibodies. HA-Spo14 remained associated with the particulate fraction although protein levels were observed to be moderately reduced in *srf1Δ* strains. Representative images are shown (n=3).
doi:10.1371/journal.pgen.1001299.g005

previously been suggested to buffer PAF toxicity, our work further suggests that the localization of PA production is also likely of importance in regulating the deleterious effects of C16:0 PAF.

PLD buffers the affects of C16:0 PAF toxicity in Neuro-2a (N2a) cells

Our chemical genomic study clearly shows that PLD activity is essential for regulating the toxic effects of C16:0 PAF. To investigate whether this observation could be extended to higher eukaryotes we investigated the role of PLD activity in conferring




Figure 6. C16:0 PAF treatment impacts the subcellular localization of PLD but not its catalytic activity. (A) In untreated (Untx) live mid-logarithmic phase cells grown at 30°C GFP-Spo14, expressed from a 2 μ plasmid (pME1096), was found to localize diffusely within the cytoplasm with modest accumulation at the peripheral membrane in both wild type (WT, YPH500) and *srf1* Δ (YKB1164) cells. Addition of vehicle (Ethanol, EtOH 0.4% v/v) did not result in any changes in GFP-Spo14 localization in comparison to untreated cells. In contrast 15 minutes of C16:0 PAF (PAF, 40 μ M) treatment resulted in a loss of peripheral membrane staining and increased aggregation of GFP-Spo14 into distinct foci in wild type (WT) but not *srf1* Δ cells. (B) Foci were quantified in wild type (YAM282-2) or *srf1* Δ (YKB2472) cells expressing GFP-Spo14 under the control of the *CUP1* promoter as described in Materials and Methods and expressed as a percentage of the total number of cells. A minimum of 300 cells for each condition from two independent experiments ($n = 2$) were assessed and presented as the mean \pm SD. (C) C16:0 PAF treatment (PAF) resulted in redistribution of a GFP-tagged phosphatidic acid binding protein, GFP-Q2 [31]. Reduced signal was associated with plasma membrane following PAF treatment in comparison to untreated (Untx) and ethanol (EtOH) treated cells. (D) Treatment with ethanol (EtOH, 0.4% v/v), C16:0 PAF or C16:0 *lyso*-PAF (40 μ M) for 30 minutes did not significantly impact the hydrolysis of BODIPY labeled glycerophosphocholine (BPC) to phosphatidic acid (PA) or phosphatidylbutanol (Pbt) in wild type cells (YPH500) transformed with empty vector (pRS415, vector) or *GFP-SPO14* (pME1096, *SPO14*). PLD activity remained associated with the particulate (P) fraction under all test conditions. C, cytosolic fraction. Representative image of 3 experiments are shown. (E) Treatment with C16:0 PAF did not affect the expression or partitioning of GFP-Spo14. Particulate (P) and cytosolic (C) fractions prepared as in (D) were separated by SDS-PAGE and analyzed by immunoblotting using anti-GFP antibodies (α GFP). Representative images are shown ($n = 2$). doi:10.1371/journal.pgen.1001299.g006

C16:0 PAF resistance to the murine neuroblastoma cell line N2a, a neural cell line previously used to study PLD and A β effects [32,33]. N2a cells were treated with C16:0 PAF or vehicle in the presence or absence of a small molecule inhibitor of PLD activity that targets both PLD1 and PLD2 with equal LC50s [34]. Treatment of N2a cells in serum-free medium with 0.1% EtOH (PAF vehicle) and 0.1% DMSO (PLD inhibitor vehicle) or with EtOH and 5 μ M PLD inhibitor did not impact upon cell viability (Figure 7, inset). As expected, addition of 1 μ M C16:0 PAF for 24 h resulted in reduced cell survival in comparison to treatment with either vehicle (Figure 7). However, treatment with C16:0 PAF in the presence of the PLD inhibitor resulted in a significant decrease in cell survival in comparison to treatment with C16:0 PAF alone or vehicle. These findings further support the role of PLD activity in regulating against C16:0 PAF mediated toxicity in mammalian neuroblastoma cells and indicate that a conserved mechanism for dealing with elevated levels of C16:0 PAF may exist within eukaryotes.

Discussion

In this study a chemical genomic screen was employed to identify the key regulators involved in buffering the toxic effects of C16:0 PAF and C16:0 *lyso*-PAF, lipid species previously shown to be elevated in neurons in response to oligomeric A β ₄₂ [1]. We identified ten deletion mutants that were sensitive to C16:0 PAF and five deletion mutants that were sensitive to C16:0 *lyso*-PAF as

compared to wild type (Figure 2A, Table S1). The dramatically different effects on growth (Figure 1) and the minimal overlap in mutants with sensitivity to either lipid suggests that C16:0 PAF, C16:0 *lyso*-PAF and potentially other PAF species, impinge upon distinct cellular pathways in yeast, which parallels the distinct PAF-mediated effects that have been reported in mammalian systems [1,35]. Such a distinction is important in light of recent evidence that aberrant metabolism, in part, underlies A β ₄₂ neurotoxicity with C16:0 PAF, but not C16:0 *lyso*-PAF or other PAF species [1,2,5].

Our unbiased chemical genomic approach identified the deletion mutant of *SRF1* as having the most significant differential sensitivity to C16:0 PAF (Figure 2B). We identified a robust interaction between Srf1-TAP and Spo14 (Figure 3), whose deletion mutant is also hypersensitive to C16:0 PAF [Figures 2B, 4 and ref. 17]. The identification of a physical interaction between Srf1 and Spo14 is striking as only two other proteins, neither with roles in PLD function, have been reported to co-purify Spo14 in high-throughput TAP studies [20]. Furthermore, biochemical assays determined that Srf1 is required for PLD activity in mitotic cells (Figures 5 and 6). A role for Srf1 in mitotic PLD activity is also supported by genome-wide synthetic lethal genetic screens which revealed that deletion mutants of both *SPO14* and *SRF1* display genetic interactions with the *sec14*-bypass mutants *CKII* and *KESI* [36]. However, in contrast to Spo14 [24,37,38], Srf1 is not essential for sporulation (Table 1) which suggests Srf1 is not regulating PLD activity in meiosis. Our results clearly show that




Figure 7. Inhibition of PLD reduces the survival of N2a cells treated with C16:0 PAF.

Undifferentiated N2a cells were treated with vehicle (0.1% DMSO + 0.1% EtOH), or PLD inhibitor (5 μ M VUO155056 + 0.1% DMSO) in serum-free media containing 0.025% BSA and cell survival assessed by Live/Dead assay at 24 h. Data are expressed as % survival standardized to control cultures maintained in complete media (dotted line). There was no significant impact of treatment conditions, vehicle treatment, or PLD inhibition on N2a survival (Student's *t*-test, $p > 0.05$, *insert*). To assess impact of PLD inhibition on C16:0 PAF sensitivity, cultures were treated with vehicle (0.1% DMSO + 0.01% EtOH), PAF (1 μ M C6:0 PAF + 0.1% DMSO), or PAF + PLD inhibitor (1 μ M C16:0 PAF + 5 μ M VUO155056). Data are expressed as % survival standardized to vehicle-treated cultures. C16:0 PAF sensitivity was significantly enhanced by PLD inhibition (ANOVA, *post-hoc* Student-Newman-Keuls multiple comparisons test, $*p < 0.05$, $**p < 0.01$). doi:10.1371/journal.pgen.1001299.g007

Srf1-TAP can co-purify Spo14 suggesting a model where Spo14 and Srf1 form a complex in mitotic cells that is required for PLD activity and to buffer the toxicity of C16:0 PAF (Figure 8).

How is Srf1 regulating PLD activity? It is unlikely that the impact of Srf1 on Spo14 protein stability (Figures 5C and S1) could explain the complete absence of PLD activity in *srf1Δ* cells. Indeed, if Srf1 was only regulating Spo14 protein levels, then overexpression of *SPO14* should have rescued the C16:0 PAF hypersensitivity of *srf1Δ* cells (Figure 4B). Additionally, it is unlikely that Srf1 is regulating PLD activity through Spo14 localization as we found that Spo14 remained associated with the particulate fraction and localized to the plasma membrane in the absence of Srf1 (Figures 5C Figure 6A, and Figure S1). How else could Srf1 be regulating Spo14? Similar to other eukaryotic PLD enzymes, Spo14 catalytic activity can be regulated by numerous mechanisms aside from changes in expression and localization. The binding of phosphoinositol phosphates, fatty acids, indirect interactions with ADP ribosylation factors (ARFs), and phosphorylation have all been demonstrated to regulate PLD activity [reviewed in 39]. Hence Srf1 may be regulating Spo14 through one of these established mechanisms. Alternatively, though we do not detect hydrolysis of phosphatidylcholine in the absence of Srf1, it is possible that some catalytic activity, possibly against other lipid




Figure 8. Model of Srf1 regulation of Spo14 activity in mitotic cells.

doi:10.1371/journal.pgen.1001299.g008

targets, is still present but misregulated. Indeed this could explain why *srf1Δ* cells display greater sensitivity to C16:0 PAF than *spo14Δ* cells (Figure 2 and Figure 4). A different explanation for this phenomenon could be attributed to the mislocalization of Spo14 in the absence of Srf1 upon C16:0 PAF treatment (Figure 6). Namely, that in the absence of Srf1, the interaction of Spo14 with other cellular factors is perturbed thereby potentially serving to titrate away other cellular factors important in the response to PAF. Deletion of *SPO14* in combination with deletion of *SRF1* would thereby alleviate C16:0 PAF toxicity to that level which is observed solely in the absence of PLD activity. The exact mechanism of how Srf1 regulates Spo14 activity will require further investigation with recombinant proteins to confirm direct interaction and reconstitute the complex activity. However, our work clearly shows that Srf1 is a novel interactor and regulator of Spo14 PLD activity in mitotic cells and together Srf1 and Spo14 are necessary to buffer the toxic effects of C16:0 PAF (Figure 8).

Our yeast chemical genomic study and murine cell culture work indicate that the role of PLD activity in buffering the cytotoxic effects of C16:0 PAF is potentially conserved across species. How is PLD buffering the toxic effect of this GPC? One possibility is that PLD is rapidly inactivating C16:0 PAF through choline hydrolysis. Indeed, human PLD has been shown to be capable of hydrolysing *lyso*-PAF species [40]. However a simpler explanation is that PA (or downstream diacylglycerol (DAG)) isoforms signal inhibition of C16:0 PAF toxicity. Indeed, expression of the *E.coli* DAG kinase, which converts DAG to PA, has been shown to suppress the toxicity of *lyso*-PAF and PAF in wild type yeast [17]. While C16:0 PAF treatment is not inhibiting the PLD catalytic activity (Figure 6B and [28]), it is causing the delocalization of GFP-Spo14 and PA concentrations from the cell periphery (Figure 6 and Figure S1). Intriguingly the C16:0 PAF-mediated delocalization of GFP-Spo14 is dependent on Srf1 (Figure 6). This suggests that the localized generation of PA (or PAF hydrolysis) may be required to buffer the toxic effects of C16:0 PAF. One possibility is that delocalization of GFP-Spo14 and decreased PA levels from the periphery may induce a transcriptional response that is necessary to survive C16:0 PAF exposure. Indeed PA has been shown to play a direct role in the transcriptional regulation of phospholipid biosynthetic genes through the transcriptional repressor Opi1 [31], and reviewed in [39]. Further, our chemical genomic screen supports this hypothesis as several genes with established roles in transcription were identified as being differentially sensitive to C16:0 PAF, including two members of the SWI/SNF chromatin remodeler complex, *SNF6* and *TAF14*, and the transcriptional regulator *UME6* (Figure 2). Although PAF has been implicated in mediating changes in gene expression, particularly those involved in responses to inflammation [41], the mechanism(s) by which these transcriptional changes occur in

response to PAF are not clearly understood, nor is it known if a PAF-mediated transcriptional response is contributing to A β -induced neuronal toxicity.

An alternative, but not mutually exclusive hypothesis, is that PLD is buffering C16:0 PAF toxicity through membrane trafficking events. Our identification of an interaction between Srf1-TAP and eisosome component Pil1 [42], suggest that PLD activity may impact sites of endocytosis. However, localization of GFP-Spo14 in either untreated or PAF treated cells (Figure 6) are not reminiscent of the eisosome patches found beneath the plasma membrane [42] nor does recent genetic epistatic miniarray profiles of plasma membrane mutants implicate Spo14 in eisosome function [43]. Alternatively, despite yeast PLD's relatively minor role in vesicle budding from the Golgi and membrane trafficking [reviewed in 39], yeast PLD may become essential for lipid membrane trafficking upon C16:0 PAF exposure. It has recently been established that PLD1 is a negative regulator of presenilin by two independent mechanisms [32,33]. Presenilins are a key component of the AD-associated γ -secretase complex, responsible for cleaving the amyloid precursor protein (APP) to A β . PLD1, but not PLD2, facilitates both APP and presenilin-1 intracellular trafficking and cell surface accumulation [33,44], however PLD1 also interacts with presenilin inhibiting γ -secretase activity [32], thus reducing A β ₄₂ production. Despite this controversy, it has been suggested that inhibiting PLD1 represents a novel therapeutic approach to reducing APP and presenilin presentation at the plasma membrane and thus retard the rate of A β ₄₂ production [44]. In this study, our unbiased approach suggests that such inhibition may be counterproductive with respect to associated GPC metabolic defects. As intraneuronal C16:0 PAF levels are elevated following exposure to soluble A β ₄₂ oligomers [1] it may be that PLD1 can inhibit the underlying C16:0 PAF ER-stress pathway by reducing A β ₄₂ production and slowing the rate of PAF accumulation. Thus careful dissection of the impact of PLD1 on A β ₄₂ production and downstream GPC-mediated signaling is warranted. Here, the discovery that PLD is required to buffer the neurotoxic effect of C16:0 PAF suggests that therapeutic strategies modulating PLD activity may be effective in ameliorating the progression of Alzheimer's Disease pathology.

Materials and Methods

Yeast strains, genetic manipulations, plasmids, and media

The yeast strains used in this study are listed in Table 2. The *MATa* deletion mutant array was purchased from OpenBiosystems (catalog no. YSC1053). Deletion strains and TAP tagged *SRF1* made for this study were designed using a standard PCR-mediated gene insertion technique [45,46]. Plasmids pME962 (*SPO14 LEU2* 2 μ), pME940 (*HA-SPO14 LEU2* CEN), pME1096 (*GFP-SPO14 LEU2* 2 μ) and pME1130 (*GFP-SPO14^{K-H} LEU2* 2 μ) were kind gifts of J. Engebrecht [24]. Plasmid expressing GFP-Q2 was a kind gift of C. Loewen [31]. Cells were grown in standard YPD or SD medium supplemented with amino acids [47], unless otherwise described. C16:0 PAF and C16:0 *lyso*-PAF (L100-0025 and L101-0025, Cedarlane Canada) and resuspended in ethanol.

Chemical-genetic profiling

The *MAT α* haploid deletion mutant array was robotically pinned in duplicate onto YPD +200 mg/L G418 plates at a density of 1536 colonies per plate using the SingerRotor HAD (Singer Instrument Company Limited) and grown for 3 days at 25°C. These plates were pinned onto YPD containing either ethanol, 120 μ M C16:0 PAF, or 120 μ M C16:0 *lyso*-PAF. Plates were incubated at 25°C and pictures taken using a Biorad Imager

at 15 and 40 hours. The sensitivity of each mutant was assessed by comparing colony sizes on the treated plates to the ethanol control plates by eye and by a computer based method using AlphaEaseFC V4.0.0 (Alpha Innotech Corporation) as described [48]. The screen was performed in triplicate and any interactions identified at least 2 out of 3 times or at least once for both lipids were confirmed by quantitative growth curves. Multiple-drug resistance (MRD) genes based on published literature [49,50] were removed from our data set.

Growth curves

Liquid growth curves were obtained for 91 strains (90 haploid knockouts plus wild type), spanning 24 plates. Each curve consisted of 45 OD readings taken at intervals of 25 minutes using Multiskan Ascent Plate Reader (Thermo Electron Corporation) and Ascent Software Version 2.6. On each plate, 6 strains were examined (wild type plus 5 others) and each strain was represented in 9 independent wells (3 replicates of the 3 treatments: ethanol, C16:0 *lyso*-PAF, and C16:0 PAF). In total, 1247 growth curves were analyzed (see Text S1 for more details).

Logistic growth curve analysis (LGCA)

A four-parameter logistic growth model was fit to the growth curves [51]:

$$y(x) = A + \frac{B - A}{1 + \exp[(x_{mid} - x)/scal]}$$

where x is time and y is the OD reading, a proxy for cell density or population size. A is the starting point of growth or minimum OD reading, B is the carrying capacity or maximum OD reading, x_{mid} is the time at 50% of total growth, and $scal$ is approximately the time taken to go from 50 to 75% of growth.

To simultaneously account for the repeated measurement of individual wells and for the systematic effects of treatment and gene deletion on growth, we fit a mixed effects logistic growth model using the R package nlme [52,53] (R code available upon request). Each of the four growth parameters (A , B , x_{mid} , $scal$) could therefore be modeled with a combination of fixed gene deletion and/or treatment effects and random well effects (see Text S1 for details). The model was fit to the ensemble of 54 curves obtained for each plate separately. To identify chemical-genetic interactions, we focused on the x_{mid} parameter. From the fitted model, we combined fixed effect estimates and predicted random well effects to produce a value of x_{mid} for each growth curve, which was treated as derived data for downstream analysis.

There was evidence of non-negligible plate effects as well as interaction effects between plates and the treatments C16:0 *lyso*-PAF and C16:0 PAF, indicating the need for inter-plate normalization (see Text S1 for details). Due to the inclusion of wild type replicates on all plates for all 3 treatments, a normalization model could be fit to the wild type x_{mid} values to obtain estimates of plate and plate-by-treatment interaction effects. These were then used to remove plate-related artifacts from all of the x_{mid} values, i.e. including those for deletion mutants.

After normalization, we fit the following model for x_{mid} :

$$x_{mid}^{(g,t)} = \alpha_{wt} + \alpha_g + \alpha_t + \alpha_{g*t} + \epsilon$$

where $x_{mid}^{(g,t)}$ is the estimated/predicted and normalized value of x_{mid} for one growth curve, corresponding to the deletion of gene g and

Table 2. Yeast strains.

Name	Genotype	Source
YPH499	<i>MATa ade2-101 his3-Δ200 leu2-Δ1 lys2-801 trp1-Δ63 ura3-52</i>	[54]
YPH500	<i>MATu ade2-101 his3-Δ200 leu2-Δ1 lys2-801 trp1-Δ63 ura3-52</i>	[54]
YKB2270	<i>MATa ade2-101 his3-Δ200 leu2-Δ1 lys2-801 trp1-Δ63 ura3-52 SRF1-TAP::TRP</i>	This study
YKB2076	<i>MATu ade2-101 his3-Δ200 leu2-Δ1 lys2-801 trp1-Δ63 ura3-52 spo14Δ::TRP</i>	This study
YKB1164	<i>MATu ade2-101 his3-Δ200 leu2-Δ1 lys2-801 trp1-Δ63 ura3-52 srf1Δ::kanMX6</i>	This study
YKB2080	<i>MATu ade2-101 his3-Δ200 leu2-Δ1 lys2-801 trp1-Δ63 ura3-52 srf1Δ::kanMX6 spo14Δ::TRP1</i>	This study
YKB2239	<i>MATa/α ade2-10/ade2-101 his3-Δ200/his3-Δ200 leu2-Δ1/leu2-Δ1 lys2-801/lys2-801 trp1-Δ63/trp1-Δ63 ura3-52/ura3-52</i>	This study
YKB2078	<i>MATa/α ade2-10/ade2-101 his3-Δ200/his3-Δ200 leu2-Δ1/leu2-Δ1 lys2-801/lys2-801 trp1-Δ63/trp1-Δ63 ura3-52/ura3-52 srf1Δ::TRP/srf1Δ::TRP</i>	This study
YKB2079	<i>MATa/α ade2-10/ade2-101 his3-Δ200/his3-Δ200 leu2-Δ1/leu2-Δ1 lys2-801/lys2-801 trp1-Δ63/trp1-Δ63 ura3-52/ura3-52 spo14Δ::TRP/spo14Δ::TRP</i>	This study
YKB2240	<i>MATa/α ade2-10/ade2-101 his3-Δ200/his3-Δ200 leu2-Δ1/leu2-Δ1 lys2-801/lys2-801 trp1-Δ63/trp1-Δ63 ura3-52/ura3-52 srf1Δ::kanMX/srf1Δ::kanMX spo14Δ::TRP/spo14Δ::TRP</i>	This study
YAM282-2	<i>MATa ura3-53 his3Δ200 leu2-Δ1 trp1-Δ63 natNT2-2-pCUP1-eGFP-SPO14</i>	[30]
YKB2472	<i>MATa ura3-53 his3Δ200 leu2-Δ1 trp1-Δ63 natNT2-2-pCUP1-eGFP-SPO14 srf1Δ::kanMX</i>	This study

doi:10.1371/journal.pgen.1001299.t002

the treatment t . The typical x_{mid} for wild type in the ethanol reference condition is given by α_{wt} and α_g and α_t are the individual effects, respectively, of deleting gene g or of treatment t . The primary parameter of interest is α_{g*t} which captures the interaction between deletion g and treatment t . Mutants deemed hypersensitive to a single PAF species were identified based on tests of the null hypotheses that $\alpha_{g*L-PAF} = 0$ or $\alpha_{g*PAF} = 0$. Mutants deemed differentially sensitive were identified based on a test of the null hypothesis that $\alpha_{g*PAF} - \alpha_{g*L-PAF} = 0$. There are 90 potential gene deletions g and 3 parameters of interest ($\alpha_{g*L-PAF}$, α_{g*PAF} , $\alpha_{g*PAF} - \alpha_{g*L-PAF}$), for a total of 270 tests. We did a global Bonferroni correction, i.e. multiplied p-values by 270, and thresholded at 0.04 to obtain hits (5 C16:0 *lyso*-PAF hypersensitive, 10 C16:0 PAF hypersensitive, 11 C16:0 PAF vs. C16:0 *lyso*-PAF differentially sensitive).

Srf1-TAP modified Chromatin Immunoprecipitation and mass spectrometry

Modified Chromatin Immunoprecipitation (mChIP) and mass spectrometry to identify co-purifying proteins was performed as previously described [22] from 2.1 L YPD culture of YKB2270 ($OD_{600} \sim 0.9$) using 300 μ L of Dynabeads (Invitrogen) coated with rabbit IgG (I5006, Sigma).

Dot assays

Cells were grown in YPD or minimal media at 30°C to mid-log phase and resuspended to an OD_{600} of 0.1 and dot assays were performed by spotting 5 μ L of five-fold serial dilutions ($OD_{600} = 0.1, 0.01, 0.001, 0.0001$) onto YPD or minimal media selection plates containing the specified concentrations of ethanol, C16:0 *lyso*-PAF or C16:0 PAF as indicated.

Sporulation assays

Strains were grown overnight in YPD at 30°C. The following day cells were pelleted at 800 g for 5 min and washed in sterile water. An OD_{600} of 2.0 was resuspended in YP-acetate and incubated at 25°C for 3 days prior to microscopic examination of sporulation efficiency. The number of spores per ascus was

enumerated in a minimum of 300 cells from three independent experiments and expressed as a percentage of total cells \pm standard error.

Microscopy

For localization of GFP-Spo14 (pME1096) and GFP-Q2 overnight cultures of yeast cells grown at 30°C in YPD medium were re-suspended at a final OD_{600} of 0.2 and allowed to reach mid-log phase prior treatment and image acquisition. Similarly, wild type (YAM282-2) and *srf1Δ* (YKB2472) cells expressing GFP-Spo14 under the control of a copper inducible promoter were grown at 30°C and induced with 3 μ M $CuSO_4$ for 2 h to induce GFP-Spo14 expression prior to imaging or extract preparation. Cells were briefly centrifuged (800 g for 3 min), resuspended in a minimal volume of growth media, spotted onto glass slides and coverslipped prior to imaging. Images were acquired using a Leica DMI 6000 fluorescent microscope (Leica Microsystems GmbH, Wetzlar Germany), equipped with a Sutter DG4 light source (Sutter Instruments, California, USA), Ludl emission filter wheel with Chroma band pass emission filters (Ludl Electronic Products Ltd., NY, USA) and Hamamatsu Orca AG camera (Hamamatsu Photonics, Herrsching am Ammersee, Germany). Images were acquired and analyzed using Velocity Software (Perkin Elmer).

Preparation of cell extracts

Overnight cultures of yeast strains cultured in YPD were diluted to an OD_{600} of 0.2 in YPD and allowed to reach mid-log growth prior to harvesting. Yeast cells were pelleted at 800 g for 5 min and washed with ice cold sterile water. Cytosolic and particulate extracts were prepared essentially as described previously [28]. Briefly, cells pellets were resuspended in 200 μ L of lysis buffer (20 mM HEPES, 150 mM NaCl, 2 mM EDTA and protease inhibitor cocktail (Sigma, P-8215)) and lysed by vortexing with glass beads. Glass beads and intact cells were first removed by brief centrifugation. Particulate and cytosolic fractions were collected and separated by centrifugation at 13 000 rpm for 15 min at 4°C. Particulate fractions were resuspended in an equal volume of lysis buffer. Protein concentration was determined using Bradford reagent.

In vitro PLD assays

Cellular and particulate extracts were added in equal volume to a reaction mixture (500 mM octylglucoside, 400 mM NaCl, 60 mM HEPES (pH 7.0) and 1% v/v n-butanol) containing 200 μ M BODIPY labeled glycerophosphocholine (2-decanoyl-1-(*O*-(11-(4,4-difluoro-5,7-dimethyl-4-bora-2a,4a-diaza-s-indacene-3-propionyl)amino)undecyl)-sn-glycero-3-phosphocholine, Invitrogen, D-3771) in the absence of exogenous PIP₂, which was not observed to affect measured PLD activity (data not shown), as previously described [28]. Reactions were incubated at 30°C for 40 min prior to spotting on TLC plates (EMD chemicals, 5626-6). Products were visualized under UV light and images captured using Quantity One 4.6.1 software (Biorad) following separation in chloroform/methanol/water/acetic acid (45:45:10:1).

Immunoblotting

10 μ g of total protein from particulate and cytosolic fractions were separated by SDS-PAGE on 5% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose at 0.8 mA/cm² for 2 h prior to blocking overnight in 5% skim milk in TBS-T. Standard Western blotting procedures were performed using α -HA (Roche, 11667149), α -GFP (Roche, 11874460001) and peroxidase-conjugated goat α -mouse IgG (BioRad, 170-6516).

N2a cell culture and survival assay

N2a cells were maintained in DMEM/F12 media containing 10% fetal bovine serum, L-glutamine and penicillin/streptomycin. Cells were plated at 1.85×10^4 cells per well in 24 well plates prior to treatment. Treatment with vehicle (0.1% DMSO + 0.1% Ethanol), the small molecule PLD inhibitor N-(2-{4-[2-oxo-2,3-dihydro-1H-benzo(d)imidazol-1-yl]piperidin-1-yl}ethyl)-2-naphthamide (VUO155056, Avanti Polar Lipids, 857370) + 0.1% EtOH, C16:0 PAF (PAF, 1 μ M) + 0.1% DMSO, or the PLD inhibitor in the presence of C16:0 PAF (PAF + Inh) were performed in serum free complete DMEM/F12 supplemented with 0.025% bovine serum albumin (BSA) for 24 h. Cell survival was assessed using LIVE/DEAD reagent (Invitrogen, L3224). Viable cells in each treatment condition were quantified and standardized to vehicle only treated cells. Data represent the results from the measurement of 4 fields of view from 3-4 independent wells per condition \pm SEM (n = 12-16). Statistical analyses were one-way analysis of variance (ANOVA) followed by *post-hoc* Student-Newman-Keuls multiple comparisons test or Student's *t* test where only two experimental groups were analyzed.

Supporting Information

Figure S1 C16:0 PAF effects the subcellular localization of GFP-Spo14 under the control of a copper inducible promoter. (A) Wild

type (YAM282-2) and *srf1* Δ (YKB2472) cells expressing GFP-Spo14 under the control of a copper inducible promoter were grown at 30°C and induced as described in the Material and Methods. GFP-Spo14 expression in live mid-logarithmic phase cells was similarly localized in untreated (Untx) and vehicle treated cells (Ethanol, 0.4%). The diffuse localization within the cytoplasm and a modest accumulation at the peripheral membrane was similar to that observed in both wild type (WT, YPH500) and *srf1* Δ (YKB1164) cells expressing *GFP-SPO14* from a 2 μ plasmid (pME1096) Figure 6A. Treatment with C16:0 PAF (PAF, 40 μ M) for 15 minutes resulted in a loss of peripheral membrane staining and increased aggregation of GFP-Spo14 into distinct foci in wild type but not *srf1* Δ cells. Foci in wild type (YAM282-2) or *srf1* Δ (YKB2472) were quantified and reported in Figure 6B. (B) Expression of GFP-Spo14 as determined by immunoblotting (α GFP) in untreated wild type (WT, YAM282-2) and *srf1* Δ (YKB2472) cells following induction with CuSO₄ for 2 h was found to be similar between both strains. Immunoblotting against glucose 6-phosphate dehydrogenase (α G6PDH) was included to ensure equal loading.

Found at: doi:10.1371/journal.pgen.1001299.s001 (2.87 MB TIF)

Table S1 Excel spreadsheet of quantitative analysis of the sensitivity of the 90 individual strains plus wildtype to C16:0 PAF and C16:0 *lyso*-PAF relative to ethanol treatment using logistic growth curve analysis.

Found at: doi:10.1371/journal.pgen.1001299.s002 (0.04 MB XLSX)

Text S1 Additional information of the logistic growth curve analysis method.

Found at: doi:10.1371/journal.pgen.1001299.s003 (0.14 MB DOC)

Acknowledgments

We thank J. Engebrecht and C. Loewen for the kind gifts of plasmids, M. Knopp for the kind gift of the GFP-Spo14 strains, and members of the Baetz Lab for their thoughtful comments.

Author Contributions

Conceived and designed the experiments: MAK DF SALB JB KB. Performed the experiments: MAK NK JPL LAS FA SALB KB. Analyzed the data: MAK NK JPL LAS SALB JB KB. Contributed reagents/materials/analysis tools: KB. Wrote the paper: MAK JPL DF SALB JB KB.

References

- Ryan SD, Whitehead SN, Swayne LA, Moffat TC, Hou W, et al. (2009) Amyloid- β 42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. *Proc Natl Acad Sci U S A* 106: 20936–20941.
- Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, et al. (2008) Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. *Nat Neurosci* 11: 1311–1318.
- Klein J (2000) Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. *J Neural Transm* 107: 1027–1063.
- Sweet RA, Panchalingam K, Pettegrew JW, McClure RJ, Hamilton RL, et al. (2002) Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. *Neurobiol Aging* 23: 547–553.
- Kriem B, Sponne I, Fife A, Malaplate-Armand C, Lozac'h-Pillot K, et al. (2005) Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. *FASEB J* 19: 85–87.
- Kita Y, Ohto T, Uozumi N, Shimizu T (2006) Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. *Biochim Biophys Acta* 1761: 1317–1322.
- Calon F, Lim GP, Yang F, Morihara T, Teter B, et al. (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. *Neuron* 43: 633–645.
- Bate C, Tayebi M, Williams A (2010) Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration. *Mol Neurodegener* 5: 13.
- Li J, Hu J, Shao B, Zhou W, Cui Y, et al. (2009) Protection of PMS777, a new AChE inhibitor with PAF antagonism, against amyloid-beta-induced neuronal apoptosis and neuroinflammation. *Cell Mol Neurobiol* 29: 589–595.
- Ryan SD, Harris CS, Mo F, Lee H, Hou ST, et al. (2007) Platelet activating factor-induced neuronal apoptosis is initiated independently of its G-protein coupled PAF receptor and is inhibited by the benzoate orsellinic acid. *J Neurochem* 103: 88–97.

11. Hoon S, St Onge RP, Giaever G, Nislow C (2008) Yeast chemical genomics and drug discovery: an update. *Trends Pharmacol Sci* 29: 499–504.
12. Khurana V, Lindquist S (2010) Modelling neurodegeneration in *Saccharomyces cerevisiae*: why cook with baker's yeast? *Nat Rev Neurosci* 11: 436–449.
13. Nielsen J (2009) Systems biology of lipid metabolism: from yeast to human. *FEBS Lett* 583: 3905–3913.
14. Nakayama R, Kumagai H, Saito K (1994) Evidence for production of platelet-activating factor by yeast *Saccharomyces cerevisiae* cells. *Biochim Biophys Acta* 1199: 137–142.
15. Nakayama R, Udagawa H, Kumagai H (1997) Changes in PAF (platelet-activating factor) production during cell cycle of yeast *Saccharomyces cerevisiae*. *Biosci Biotechnol Biochem* 61: 631–635.
16. Nakayama R, Yun C, Tamaki H, Saito K, Kumagai H (1996) Physiological action of PAF in yeast *Saccharomyces cerevisiae*. *Adv Exp Med Biol* 416: 45–50.
17. Zarembeg V, McMaster CR (2002) Differential partitioning of lipids metabolized by separate yeast glycerol-3-phosphate acyltransferases reveals that phospholipase D generation of phosphatidic acid mediates sensitivity to choline-containing lysolipids and drugs. *J Biol Chem* 277: 39035–39044.
18. Zarembeg V, Gajate C, Cacharro LM, Mollinedo F, McMaster CR (2005) Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition. *J Biol Chem* 280: 38047–38058.
19. Brewer C, Bonin F, Bullock P, Nault MC, Morin J, et al. (2002) Platelet activating factor-induced apoptosis is inhibited by ectopic expression of the platelet activating factor G-protein coupled receptor. *J Neurochem* 82: 1502–1511.
20. Gavin AC, Aloy P, Grandi P, Krause R, Boesche M, et al. (2006) Proteome survey reveals modularity of the yeast cell machinery. *Nature* 440: 631–636.
21. Krogan NJ, Cagney G, Yu H, Zhong G, Guo X, et al. (2006) Global landscape of protein complexes in the yeast *Saccharomyces cerevisiae*. *Nature* 440: 637–643.
22. Lambert JP, Mitchell L, Rudner A, Baetz K, Figey D (2009) A novel proteomics approach for the discovery of chromatin-associated protein networks. *Mol Cell Proteomics* 8: 870–882.
23. Lambert JP, Baetz K, Figey D (2010) Of proteins and DNA—proteomic role in the field of chromatin research. *Mol Biosyst* 6: 30–37.
24. Rudge SA, Morris AJ, Engebrecht J (1998) Relocalization of phospholipase D activity mediates membrane formation during meiosis. *J Cell Biol* 140: 81–90.
25. Honigberg SM, Conicella C, Esposito RE (1992) Commitment to meiosis in *Saccharomyces cerevisiae*: involvement of the SPO14 gene. *Genetics* 130: 703–716.
26. Connolly JE, Engebrecht J (2006) The Arf-GTPase-activating protein Gcs1p is essential for sporulation and regulates the phospholipase D Spo14p. *Eukaryot Cell* 5: 112–124.
27. Marston AL, Tham WH, Shah H, Amon A (2004) A genome-wide screen identifies genes required for centromeric cohesion. *Science* 303: 1367–1370.
28. Ella KM, Dolan JW, Meier KE (1995) Characterization of a regulated form of phospholipase D in the yeast *Saccharomyces cerevisiae*. *Biochem J* 307 (Pt 3): 799–805.
29. Ella KM, Meier GP, Bradshaw CD, Huffman KM, Spivey EC, et al. (1994) A fluorescent assay for agonist-activated phospholipase D in mammalian cell extracts. *Anal Biochem* 218: 136–142.
30. Riedel CG, Mazza M, Maier P, Korner R, Knop M (2005) Differential requirement for phospholipase D/Spo14 and its novel interactor Smal for regulation of exocytotic vesicle fusion in yeast meiosis. *J Biol Chem* 280: 37846–37852.
31. Loewen CJ, Gaspar ML, Jesch SA, Delon C, Krstakis NT, et al. (2004) Phospholipid metabolism regulated by a transcription factor sensing phosphatidic acid. *Science* 304: 1644–1647.
32. Cai D, Netzer WJ, Zhong M, Lin Y, Du G, et al. (2006) Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. *Proc Natl Acad Sci U S A* 103: 1941–1946.
33. Cai D, Zhong M, Wang R, Netzer WJ, Shields D, et al. (2006) Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. *Proc Natl Acad Sci U S A* 103: 1936–1940.
34. Scott SA, Selvy PE, Buck JR, Cho HP, Criswell TL, et al. (2009) Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. *Nat Chem Biol* 5: 108–117.
35. Ryan SD, Harris CS, Carswell CL, Baenziger JE, Bennett SA (2008) Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. *J Lipid Res* 49: 2250–2258.
36. Fairn GD, Curwin AJ, Stefan CJ, McMaster CR (2007) The oxysterol binding protein Kes1p regulates Golgi apparatus phosphatidylinositol-4-phosphate function. *Proc Natl Acad Sci U S A* 104: 15352–15357.
37. Rose K, Rudge SA, Frohman MA, Morris AJ, Engebrecht J (1995) Phospholipase D signaling is essential for meiosis. *Proc Natl Acad Sci U S A* 92: 12151–12155.
38. Rudge SA, Cavenagh MM, Kamath R, Sciorra VA, Morris AJ, et al. (1998) ADP-Ribosylation factors do not activate yeast phospholipase Ds but are required for sporulation. *Mol Biol Cell* 9: 2025–2036.
39. Mendonsa R, Engebrecht J (2009) Phospholipase D function in *Saccharomyces cerevisiae*. *Biochim Biophys Acta* 1791: 970–974.
40. Pai JK, Siegel MI, Egan RW, Billah MM (1988) Phospholipase D catalyzes phospholipid metabolism in chemotactic peptide-stimulated HL-60 granulocytes. *J Biol Chem* 263: 12472–12477.
41. Kihara Y, Ishii S, Kita Y, Toda A, Shimada A, et al. (2005) Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. *J Exp Med* 202: 853–863.
42. Walther TC, Brickner JH, Aguilar PS, Bernales S, Pantoja C, et al. (2006) Eisosomes mark static sites of endocytosis. *Nature* 439: 998–1003.
43. Aguilar PS, Frohlich F, Rehman M, Shales M, Ulitsky I, et al. (2010) A plasma-membrane E-MAP reveals links of the eisosome with sphingolipid metabolism and endosomal trafficking. *Nat Struct Mol Biol*.
44. Oliveira TG, Di Paolo G (2010) Phospholipase D in brain function and Alzheimer's disease. *Biochim Biophys Acta* 1801: 799–805.
45. Longtine MS, McKenzie A, 3rd, Demarini DJ, Shah NG, Wach A, et al. (1998) Additional modules for versatile and economical PCR-based gene deletion and modification in *Saccharomyces cerevisiae*. *Yeast* 14: 953–961.
46. Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M, et al. (1999) A generic protein purification method for protein complex characterization and proteome exploration. *Nat Biotechnol* 17: 1030–1032.
47. Abelson JN, Simon ML, Guthrie C, Fink GR (2004) *Guide to Yeast Genetics and Molecular Biology*. California: Elsevier Academic Press.
48. Memarian N, Jessulat M, Alirezaie J, Mir-Rashed N, Xu J, et al. (2007) Colony size measurement of the yeast gene deletion strains for functional genomics. *BMC Bioinformatics* 8: 117.
49. Parsons AB, Brost RL, Ding H, Li Z, Zhang C, et al. (2004) Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. *Nat Biotechnol* 22: 62–69.
50. Parsons AB, Lopez A, Givoni IE, Williams DE, Gray CA, et al. (2006) Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. *Cell* 126: 611–625.
51. Pinheiro JC, Bates DM (2000) *Mixed-Effects Models in S and S-Plus*; Chambers J, editor. New York: Springer.
52. Pinheiro JC, Bates DM, DebRoy S, Sarkar D (2008) *nlme: Linear and Nonlinear Mixed Effects Models*. R package 3.1-90 ed ed.
53. Team RDC (2008) *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing.
54. Sikorski RS, Hieter P (1989) A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics* 122: 19–27.